Introduction
Gene amplification is a mechanism for increasing gene copy number, and is observed in nearly all types of solid tumors (Schwab, 1999) . Proteins encoded by amplified genes are frequently involved in promoting cell proliferation, as exemplified by MYCN (2p24) in neuroblastoma (Schwab et al., 1983) , CDK4 (12q13-14) in softtissue sarcoma (Khatib et al., 1993) , and HER2/NEU (17q11-12) as well as CYCD1 (11q13) in breast cancer (King et al., 1985; Schuuring et al., 1992) .
Results from several studies have shown that amplifications encompass megabase regions of genomic DNA that often contain genes neighboring the amplification target sequence (Tanigami et al., 1992; Forus et al., 1993; Tomasetto et al., 1995) . These neighboring genes can be considered as coamplified bystanders, examples of which are DDX1 at 2p24 (Amler et al., 1996) , TOPOIIa at 17q11-12 (Smith et al., 1993) , and GLI at 12q13-14 (Forus et al., 1993) . Although bystander gene amplification has been shown to occur in many different types of solid tumor, the functional and/or biological consequences of such amplifications have been largely unexplored. In the case of EGFR amplification, the two most frequently coamplified bystander genes are LANCL2 (Lanthionine Synthetase C-like 2) and ECOP (EGFR-Coamplified and Overexpressed Protein; sequence corresponding to GenBank Identification Number 31542523) (Wang et al., 1998; Eley et al., 2002) . Previously, we investigated the role of LanCl-2 in modulating chemotherapeutic response in tumor cells (Park and James, 2003) . ECop, which is amplified and overexpressed in at least a third of glioblastomas with EGFR amplification (Eley et al., 2002) , was recently identified as one of several hundred genes whose ectopic expression increases NF-kB luciferase reporter activity (Matsuda et al., 2003) . In the present study, we have examined the functional role of ECop in NF-kB signaling.
The NF-kB/Rel family is a group of inducible transcription factors that consist of p65/RelA, c-Rel, RelB, p105/p50 and p100/p52. These family members form homo-or hetero-dimers, with the p65 : p50 heterodimer, that is generally referred to as NF-kB, being the most abundant form. NF-kB activity is regulated by at least five different IkB isoforms, and of these, IkBa is best characterized (Whiteside and Israel, 1997; Karin and Ben-Neriah, 2000) . In unstimulated cells, IkBa is associated with NF-kB, thereby, preventing NF-kB from binding its cognate promoter and also causing its steady-state localization to the cytoplasm. In contrast, in cells stimulated with activating signals such as TNFa, IkBa is rapidly targeted for proteasomemediated degradation via phosphorylation-dependent ubiquitination (Karin and Ben-Neriah, 2000) . IkBa degradation allows NF-kB to translocate to the nucleus and induce the transcription of target genes that are important in diverse cellular processes such as immune and inflammatory response, proliferation, and apoptosis. Termination of NF-kB activity is mediated by new synthesis of IkBa, that is also transcriptionally induced by NF-kB as an autoregulatory negative feedback; newly synthesized IkBa dissociates NF-kB from kB enhancer element and exports NF-kB back to the cytoplasm (Karin and Ben-Neriah, 2000) .
In this report, we demonstrate that ECop is a key effector of NF-kB signaling, and that a mechanism underlying this relationship involves ECop's effect on IkBa degradation. Our results also suggest that ECopinduced NF-kB activation is important for the regulation of cellular apoptotic response.
Results

ECop increases the transcriptional activity of NF-kB
To address whether endogenous NF-kB activation is affected by ectopic ECop expression, we cotransfected 293T cells with wild-type or mutant NF-kB reporter, and either V5-tagged ECop or empty expression vector ( Figure 1a) . NF-kB transcriptional activity in ECoptransfected cells increased by five-fold as compared to vector-transfected cells (Figure 1a ). Cells transfected with a mutant NF-kB reporter did not show an ECopassociated stimulatory effect on NF-kB activity ( Figure 1a) . As a further control to ensure that ECopmediated NF-kB activation results in increased NF-kB reporter activity, we overexpressed IkBa, the inhibitory subunit of NF-kB in ECop-transfected cells, and this abolished the stimulatory effect of ECop on NF-kB activation ( Figure 1a ). Transfecting cells with increasing amounts of ECop cDNA resulted in a corresponding increase in reporter activity in a dose-dependent manner (Figure 1b) .
To determine whether ectopic ECop expression influences cytokine-induced NF-kB activation, ECop transfectants were stimulated with IL-1b or TNFa (Figure 1c ) IL-1b treatment resulted in a three-fold increase in NF-kB reporter activity in ECop-transfected cells, as compared to cells transfected with empty vector, while TNFa treatment induced a 1.5-fold increase in NF-kB reporter activity (Figure 1c ). ECop-associated increases in NF-kB transcriptional activity, either in the presence or absence of cytokine stimulus, do not appear to involve alterations in cellular levels of p65, p50, or IkBa ( Figure 3b and data not shown).
To address whether the ectopic expression of proteins unrelated to NF-kB signaling would stimulate transcription of the NF-kB reporter construct, we transfected cells using the same expression vector as before, but containing cDNAs encoding EGFR, serum albumin and LanCl-2; none of these affected NF-kB reporter activity (Figure 1d ). We also examined whether ECop specifically affects NF-kB, or also affects AP-1, which shares upstream signaling components with NF-kB (Liu et al., 1996) . For this, we cotransfected cells with AP-1 luciferase reporter and either empty vector, V5-tagged ECop, or c-Jun. The associated results showed that AP-1 reporter activity is not affected by ectopic ECop expression (Figure 1e ), supporting a specificity of the relationship between ECop and NF-kB.
ECop enhances DNA binding of NF-kB
To examine whether the ECop-associated stimulation of NF-kB transcriptional activity is due to increased ECop, a key effector of NF-jB signaling and apoptosis S Park and CD James NF-kB DNA binding, an electrophoretic mobility shift assay (EMSA) was performed by incubating 32 P-labeled NF-kB consensus oligo with nuclear extracts from either vector-transfected or ECop-transfected cells. Ectopic expression of ECop preferentially increased p65-p50 : DNA complex formation as compared to vector-transfected cells (Figure 2a , lanes 1 and 2). NF-kB : DNA complexes in ECop-as well as in vectortransfected cells were abolished by the addition of excess unlabeled consensus oligo (lanes 3 and 4), but unaffected by the addition of excess mutant oligo (lanes 5 and 6). Addition of anti-p65 or anti-p50 antibody to nuclear extracts from ECop-transfected cells produced the expected antibody : NF-kB : DNA supershifts (lanes 7-12).
To determine whether ECop overexpression promotes NF-kB nuclear translocation, we performed immunocytochemistry analysis of vector vs ECop-V5 transfected cells ( Figure 2b ). The results indicate an approximate two-fold increase in nuclear p65 by ECop overexpression, with an abundance of ECop at the nuclear and perinuclear regions ( Figure 2b) ; similar results were obtained with antibody against endogenous ECop (Figure 2c ). Western blot analysis of the cytosolic vs nuclear fractions of ECop-V5 transfectants showed nuclear enrichment for ectopically expressed ECop as well as for endogenous ECop (data not shown). This subcellular localization of ECop did not change in response to cytokine stimuli (data not shown).
ECop enhances the anti-apoptotic effect of NF-kB
We next examined whether ECop-mediated NF-kB activation promotes resistance to apoptosis by exposing Figure 2 ECop increases NF-kB binding to the kB enhancer element and promotes nuclear translocation of p65. (a) Nuclear extracts from HeLa cells, transfected with the indicated plasmids, were prepared at 30 h post-transfection. For the competitive binding assays (lanes 3-6), 50-fold excess of cold wild-type (wt) or mutant (mut) oligo was added to reaction mixtures prior to the addition of 32 Plabeled kB enhancer probe. For antibody supershift assays (lanes 7-12, and lanes 16-18), 1 mg of anti-p65 or anti-p50 antibody was added to the reaction mixtures. As controls, nuclear extracts from p65-and/or p50-transfectants generated prominent bands representing p65-p65, p65-p50 and p50-p50 NF-kB dimers (lanes 13-15), with identical electrophorectic mobilities to those in lanes 1 and 2. (n.s. ¼ nonspecific binding of the 32 P-labeled probe). (b) At 30 h post-transfection, HeLa cells transfected with empty vector or ECop-V5 were processed for immunocytochemistry by costaining with anti-V5 and anti-p65 antibodies, followed by anti-mouse Alexagreen G488 and anti-rabbit Alexa-red G594 secondary antibodies, respectively. (c) Immunocytochemistry was conducted in HeLa cells with preimmune, or rabbit polyclonal anti-ECop sera, followed by anti-rabbit Alexa-green G488. Confocal imaging was performed at Â 40 magnification ECop, a key effector of NF-jB signaling and apoptosis S Park and CD James vector-and ECop-transfected cells to simultaneous treatment with TNFa and cycloheximide (Beg and Baltimore, 1996; Van Antwerp et al., 1996) . At 24 h subsequent to treatment, approximately 60% of vectortransfected cells underwent apoptosis, whereas only 30% of ECop-transfected cells were apoptotic (Figure 3a) . When TNFa and cycloheximide treatment was extended to 36 h, approximately 50% of ECoptransfected cells remained viable, as compared to only 15% of vector-transfected cells (Figure 3a) .
To investigate the molecular basis of the antiapoptotic response in ECop-transfected cells, we examined treated cells for levels of p85 PARP fragment and procaspase-3. Western blot results showed decreased cleavage for both PARP and procapase-3 in ECoptransfected cells (Figure 3b ).
ECop knockdown inhibits NF-kB activation by delaying IkBa degradation
Next, we examined whether reductions of endogenous ECop expression, via small interfering RNA (siRNA) treatment, inhibit NF-kB activation. Analysis of multiple incubation times with ECop-specific siRNA showed that 48 h treatment results in significant decreases in ECop expression in HeLa cells (Figure 4a ), and reduced NF-kB reporter activity by approximately eight-fold as compared to nonspecific siRNA-treated cells (Figure 4b) . Also, TNFa and IL-1b treatment resulted in 14-fold and three-fold reductions of NF-kB reporter activity, respectively, in ECop knockdown cells, relative to nonspecific siRNA controls (Figure 4b) .
As the NF-kB activity was reduced to the greatest extent in ECop knockdown cells treated with TNFa (Figure 4b ), we focused subsequent analyses on TNFastimulated conditions to determine a molecular basis of NF-kB inhibition resulting from the reduction of endogenous ECop expression. For this purpose, we examined IkBa degradation, a requisite event for NF-kB induction, by performing a time-course analysis of cellular IkBa in nonspecific vs ECop-specific siRNAtreated cells (Figure 4c ). In nonspecific siRNA-treated cells IkBa degradation was complete within 15 min of TNFa stimulation, and new IkBa synthesis, first evident at 60 min of TNFa treatment, completely restored the cellular pool of IkBa within 2 h ( Figure 4c) ; these rates of IkBa degradation and resynthesis are consistent with those indicated in other studies (Karin and Ben-Neriah, 2000; Anest et al., 2003) . In contrast, ECop knockdown resulted in a severe delay in IkBa degradation that was To determine whether a delay in IkBa degradation by ECop protein knockdown is associated with a corresponding delay in NF-kB activation, we examined the kinetics of p65 nuclear translocation. Our Western blot analysis showed a noticeable delay in the nuclear translocation kinetics of p65 in ECop knockdown cells as compared to nonspecific siRNA-treated cells ( Figure 5a ). We, then, performed EMSA to examine the induction of NF-kB DNA binding activity. In nonspecific siRNA-treated cells, NF-kB DNA binding peaked as early as 15 min and persisted at peak level until 60 min of TNFa stimulation (Figure 5b ). In contrast, NF-kB DNA binding in ECop knockdown cells was significantly reduced at early time points (15 and 30 min) and did not achieve a maximal level until 60 min (Figure 5b ). In order to distinguish whether delayed IkBa degradation in ECop knockdown cells is due to ECop's effect on IkBa proteolysis, or rather is due to its effect on upstream signaling events, we examined IKKb activation and IkBa phosphorylation since these two events occur prior to IkBa degradation (Karin and BenNeriah, 2000) . The results of this analysis showed no appreciable difference in IkBa phosphorylation or IKKb activation in ECop siRNA-treated cells vs nonspecific siRNA-treated cells, suggesting that ECop's role in regulating NF-kB activity is specifically mediated through its effects on IkBa degradation (Figure 6 ).
ECop knockdown sensitizes cells to apoptosis
In contrast to the antiapoptotic effect of ECop overexpression (Figure 3) , the effect of ECop knockdown is pro-apoptotic. At 48 h after the ECop siRNA treatment, condensed or fragmented nuclei, that are morphological indicators of apoptosis, became noticeable in ECop knockdown cells, while nonspecific siRNA-treated cells remained perfectly healthy (Figure 7a ). Apoptotic challenge (TNFa þ cycloheximide) resulted in a substantial level of apoptosis in ECop knockdown cells, whereas cells treated with nonspecific siRNA displayed an extent of apoptosis comparable to ECop knockdown cells without apoptotic challenge (Figure 7a ). The increased apoptosis of cells treated with ECop siRNA was further supported by Western blot analysis which showed increased amount of p85 PARP fragment in ECop knockdown cells as compared with nonspecific siRNA-treated control (Figure 7b ).
Discussion
Previously, we reported that EGFR amplicons (7p11.2) contain multiple bystander genes, and of these, LANCL2 and ECOP are the closest to EGFR and are most often coamplified with EGFR (frequencies of 50 and 35% respectively) (Eley et al., 2002) . In our initial study involving potential consequences of bystander gene amplification and overexpression, we demonstrated that LanCl-2 has a role in modulating cellular response to adriamycin by influencing multidrug resistance gene (MDR1) transcription (Park and James, 2003) . A second Figure 5 Delayed IkBa degradation by ECop knockdown diminishes NF-kB DNA binding in association with delayed p65 nuclear translocation. (a) HeLa cells were treated with nonspecific (Ns) or ECop-specific siRNA for 48 h. Following stimulation with 10 ng/ml TNFa for the indicated time periods, nuclear fractions were obtained and 30 mg of total protein was processed for SDS-PAGE and Western blot with antibodies against the indicated proteins. ORC2 and Grb2 were used as nuclear and cytosolic markers, respectively. (b) HeLa cells were treated as in (a), and at the end of each incubation, nuclear extracts were prepared for EMSA using 32 P-labeled kB enhancer probe (n.s. ¼ non-specific binding of the probe) Figure 6 ECop knockdown does not affect either IKKb activation or IkBa phosphorylation. HeLa cells were treated with nonspecific (Ns) or ECop-specific siRNA for 48 h, and stimulated with 10 ng/ ml TNFa for the indicated time periods. Total lysates were obtained and processed for Western blot analysis with antibodies against the indicated proteins ECop, a key effector of NF-jB signaling and apoptosis S Park and CD James novel bystander, ECOP, was identified as one of several hundred genes whose ectopic expression activates an NF-kB luciferase reporter (Matsuda et al., 2003) . In combination with our previous determination of frequent amplification of ECOP in EGFR amplicons (Wang et al., 1998) , the results of this study motivated the current analysis of ECop's relationship with NF-kB signaling.
In the present study, we have shown that ECop is expressed as a protein (see Figures 4-7) , with an apparent molecular weight of 18 kDa that is consistent with the molecular weight predicted from its aminoacid sequence. ECop does not appear to contain previously known functional domains or motifs, other than a potential signal peptide that could serve to target ECop to the plasma membrane, endoplasmic reticulum (ER), or the extracellular compartment (Alberts et al., 1994) . Our immunocytochemical analysis excluded the former of these possibilities (Figure 2b, c) , and extracellular secretion of ECop was excluded through negative Western blot results of concentrated tissue culture supernatants from ECop-V5-transfected cells as well as from MDA468 cells with ECop amplification and overexpression (data not shown). Instead, we have found both endogenous and ectopically expressed ECop are enriched at the nuclear and perinuclear regions (Figure 2b, c) .
Our data show that ectopic expression of ECop increases the transcriptional activity of NF-kB by facilitating NF-kB nuclear translocation and DNA binding (Figure 2a, b) , and that this, in turn, confers cellular resistance to apoptotic stimuli, such as TNFa and cycloheximide (Figure 3) . Importantly, we have demonstrated that a reduction in endogenous ECop protein expression, via siRNA knockdown, significantly decreases NF-kB activity (Figures 4b, c and 5b ) and induces cellular apoptosis (Figure 7 ). This appears to be attributable to ECop's role in the temporal regulation of IkBa degradation, that was made evident in time-course analysis of IkBa cellular levels in nonspecific vs ECopspecific siRNA-treated cells (Figure 4c ). In nonspecific siRNA-treated control, IkBa degradation was complete by 15 min with rapid induction of NF-kB DNA binding. In contrast, both the initiation and completion of IkBa degradation was delayed in ECop knockdown cells (Figure 4c ), and this delay resulted in the inhibition of NF-kB DNA-binding activity ( Figure 5b) . As a result, NF-kB transcriptional activity was compromised as evidenced by the decreased expression of the NF-kB target gene, IkBa (Figure 4c ; 60, 120 and 240 min).
ECop's effects on the temporal regulation of IkBa were clearly evident in association with TNFa stimulation of ECop knockdown cells (Figure 4c ), but were not apparent when examining the steady-state level of IkBa in unstimulated cells (Figure 4c, time zero) , or in association with the ectopic expression of ECop (data not shown). These observations suggest the existence of IkBa-dependent as well as IkBa-independent function of ECop in modulating NF-kB activity.
Although we did not find indication of direct interaction between ECop and the major components of NF-kB signaling (IkBa, p65, IKKs, TRAF2 and TRAF6) through coimmunoprecipitation experiments (data not shown), we have determined that ECop binds to Csn5/Jab1 (manuscript in preparation), a key subunit of the COP9 signalosome (Wei and Deng, 2003) . The COP9 signalosome has been implicated for its role in ubiquitin-proteasome-mediated protein degradation as well as signal transduction (Wei and Deng, 2003) . Therefore, it is conceivable that a physical interaction between ECop and Csn5 could influence ubiquitindependent IkBa degradation (manuscript in preparation).
The increased apoptosis observed in ECop knockdown cells (Figure 7) highlights the importance of ECop in NF-kB signaling. Under circumstances where ECop is aberrantly expressed, the balance between pro-and antiapoptotic responses would be upset (Karin and Lin, 2002; Kucharczak et al., 2003) and could, for instance, result in increased cell death in ECop-deficient cells subjected to apoptotic challenge. In contrast, increased ECop expression, such as would occur in cancers with ECOP amplification (Wang et al., 1998) , could confer cellular resistance to apoptosis. As a result of the number of disease states that have been associated with elevated NF-kB activity, such as arthritis, asthma, chronic inflammation, and various types of cancer , a substantial amount of effort has ECop, a key effector of NF-jB signaling and apoptosis S Park and CD James been directed toward the development of NF-kBtargeted therapies (Amit and Ben-Neriah, 2003) . The results presented here suggest that further study of ECop's role in regulating NF-kB activity may provide insights important to refining such therapeutic strategies.
Materials and methods
Cell lines, plasmids and reagents
The 293 T cell line was purchased from American Type Culture Collection (ATCC). HeLa cells were kindly provided by James D Orth (Mayo Foundation and Graduate School). All cell lines were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. 293T/pcDNA3.1-V5/His and 293T/ECop-V5 stable cell lines were selected and maintained in 600 mg/ml G418-containing medium.
Open reading frames of ECop, EGFR, LanCl-2, serum albumin and IkBa were PCR-amplified and cloned into the pcDNA3.1-V5/His expression vector (Invitrogen); For EGFR and IkBa cDNA, stop codons were included to eliminate Cterminal V5/His tags. All expression constructs were sequenceverified by dye terminator sequencing analysis at the Molecular Biology Core Facility (Mayo Foundation and Graduate School). Wild-type NF-kB luciferase construct, that contains five consecutive NF-kB-binding sites, (T GGGGACTTTCC GC) 5 , was purchased from Stratagene. A mutant NF-kB luciferase construct, containing GGG to CTC substitution in NF-kB-binding site, was generated by inserting (TGC TCACTTTCC GC) 5 into a multiple cloning site of pLuc-MCS vector (Stratagene). Wild-type NF-kB consensus oligo and AP-1 luciferase reporter construct were obtained from Promega. The p65 and p50 cDNA constructs were generously provided by Mr Gary Bren (Mayo Foundation and Graduate School). The c-Jun plasmid was a kind gift from Dr Ralf Janknecht (Mayo Foundation and Graduate School). All transfections were performed using Lipofectamine and Plus reagent according to the manufacturer's protocol (Invitrogen).
Antibodies against p65, p50, IkBa, IkBb, IKKb and Grb2 were from Santa Cruz Biotechnology, and anti-V5 antibody was from Invitrogen. Antibodies against phospho-IkBa and phospho-IKKb were purchased from Cell Signaling. Rabbit polyclonal sera specific for ECop was developed against the peptide sequence EPAFNVSYTRQPPNPGPG, which represent amino acids 93-110 of ECop (Cocalico Biologicals Inc.). Anti-p85 PARP antibody was purchased from Promega and anti-procaspase 3 antibody was obtained from Transduction laboratories. TNFa and IL-1b were purchased from Calbiochem, and cycloheximide was obtained from Sigma.
NF-kB reporter assay
Cells were seeded at 60% density in six-well plates in triplicate 1 day before transfection. The next day, NF-kB luciferase reporter construct was cotransfected with the indicated cDNA constructs (see Results and associated figures), and a bgalactosidase control vector. pcDNA3.1-V5/His was added to standardize the amount of cDNA used in the transfections. At 24-30 h post-transfection, cells were washed once with phosphate-buffered saline (PBS) and then harvested for the measurement of luciferase activity (Luciferase Assay System, Promega), following the manufacturer's protocol. b-Galactosidase activity was measured using the b-Galactosidase Assay System (Promega) to correct for transfection efficiency.
Immunocytochemistry
Immunocytochemistry was performed as described in Park and James (2003) . For DAPI staining, cells were grown on coverslips in six-well plates, and then treated with siRNA delivered by Oligofectamine (Invitrogen), following the manufacturer's protocol. At 48 h after siRNA treatment, cells were fixed using 3% paraformaldehyde as described in Park and James (2003) , and then mounted on glass slides using Vectashield DAPI-containing mounting medium (Vector laboratories). Imaging was performed using a Zeiss LSM510 confocal microscope.
Western blot analysis of nuclear fraction
Nuclear fractionation was performed following procedures described in Birbach et al. (2002) . An amount of 30-50 mg of protein was resolved on 12% Tris-glycine gels, with subsequent Western blot analysis performed as previously described (Park and James, 2003) .
Electrophoretic mobility shift assay
Nuclear extracts for EMSA were prepared as described in Kawai et al. (2002) . kB enhancer oligonucleotide probe (Promega) was end-labeled with 5 0 -[g-32 P]-ATP using T4 kinase (Invitrogen) at 371C for 10 min and purified using Sephadex G-25 (fine) columns (Roche). In total, 60 000-100 000 c.p.m. of 32 P-labeled kB enhancer oligonucleotide probe was added to each reaction mixture containing 1-3 mg of protein in gel shift assay buffer (10 mM Tris-HCl, pH 7.5; 50 mM NaCl; 0.5 mM DTT; 0.5 mM EDTA; 1 mM MgCl 2 and 4% glycerol), 1 mg polydIdC, and 5 mg of BSA in a total reaction volume of 20 ml. Reaction mixtures were incubated at room temperature for 20 min. For antibody supershifts, 1 mg of anti-p65 or p50 antibodies were incubated in reaction mixtures on ice for 10 min prior to the addition of 32 P-labeled probe. The reaction mixtures were resolved in a 6% DNA retardation gel (Invitrogen) in 0.5 Â TBE buffer. Gels were dried and exposed to X-ray film at À701C.
Apoptosis assay
Cells were treated with TNFa (10 ng/ml) and cycloheximide (50 mg/ml) for 14 h prior to Western blot analysis, or for 24 or 36 h prior to the trypan blue staining. Detached cells were saved and combined with cells obtained after trypsinization. Collected cells were centrifuged at 1000 g for 3 min, and washed once with cold PBS. For Trypan blue staining, cell pellets were resuspended in 1 ml PBS, and 100 ml of each suspension was mixed with 100 ml of trypan blue solution for 15 min. A volume of 10 ml of each mixture was used for scoring total cells as well as stained cells on a dual-chamber hemocytometer.
To detect levels of cleaved PARP or procaspase 3, cells were lysed in cold RIPA buffer supplemented with protease inhibitors (Roche) and 2 mM PMSF. Equal amounts of protein were loaded on 12% Tris-glycine gels, electrophoresed and then transferred to a PVDF membrane for Western blot analysis.
Small interfering RNA
ECop siRNA oligos are 5 0 -GGACUCUAUCCAACCUA UUdTdT-3 0 (Esi) and 5 0 -UUGCUGGUAUUUCGAAGG AdTdT-3 0 (E 0 si) (determined using the siRNA design tool, ECop, a key effector of NF-jB signaling and apoptosis S Park and CD James Dharmacon) and were synthesized as duplex ready, 2 0 -deprotected form by Dharmacon. Nonspecific siRNA with identical GC content as the ECop siRNA (42%) was used as a control (Dharmacon). siRNA was introduced to cells using Oligofectamine (Invitrogen), following the manufacturer's protocol.
